FDA names interim director to women's health post
She replaces Susan Wood, who quit this month in protest after the agency refused to permit OTC sales of Barr's Plan B emergency contraceptive -- a decision Wood said was politically-motivated.
Toigo is an FDA veteran who also heads the agency's Office of Special Health Issues.
The FDA will conduct a search for a permanent replacement, an FDA spokeswoman told MM&M, although a timeframe for finding a permanent OWH director is not being given.
Lester Crawford, FDA commissioner, announced Toigo's appointment last Friday.
Crawford's own confirmation had been held up by Senate Democrats until the administration set a Sept. 1 deadline for FDA to make a decision on Plan B.
On Aug. 26, however, Crawford ordered a 60-day public comment period on Plan B, saying the regulatory and policy issues raised by Barr's application -- notably, whether Plan B can switch to OTC status for women ages 16 and older and remain prescription-only for those under 16 -- were too weighty to be decided behind closed doors.